Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Assets (2017 - 2025)

Crinetics Pharmaceuticals has reported Assets over the past 9 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Assets at $1.1 billion for Q4 2025, down 21.49% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 21.49% YoY), and the annual figure for FY2025 was $1.1 billion, down 21.49%.
  • Assets for Q4 2025 was $1.1 billion at Crinetics Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Over the last five years, Assets for CRNX hit a ceiling of $1.4 billion in Q4 2024 and a floor of $163.5 million in Q1 2021.
  • Median Assets over the past 5 years was $528.5 million (2022), compared with a mean of $678.8 million.
  • Biggest five-year swings in Assets: plummeted 30.46% in 2023 and later soared 219.02% in 2024.
  • Crinetics Pharmaceuticals' Assets stood at $351.0 million in 2021, then increased by 0.33% to $352.2 million in 2022, then surged by 80.41% to $635.4 million in 2023, then surged by 125.79% to $1.4 billion in 2024, then dropped by 21.49% to $1.1 billion in 2025.
  • The last three reported values for Assets were $1.1 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.